Objective. We sought to evaluate the safety, tolerability, and patterns of use for the once-daily oral, narrow-spectrum antibiotic sarecycline in patients with moderate-to-severe acne vulgaris during a 40-week Phase III, multicenter, open-label extension study.
J Clin Aesthet Dermatol. 2019;12(10):16–23 by Linda Stein Gold, MD; Sunil Dhawan, MD; Jonathan Weiss, MD; Zoe Diana Draelos, MD; Herman Ellman, MD; and Iain Stuart, PhD Dr. Stein Gold is with the Henry Ford Health System in Detroit, Michigan. Dr. Dhawan is with the Center for Dermatology Clinical Research, Inc., in Fremont, California. Dr. Weiss
by Srinivas Sidgiddi, MD; Kent Allenby, MD; Franklin Okumu, PhD; and Anirudh Gautam, MPharm Drs. Sidgiddi, Allenby, and Okumu are with Promius Pharma in Princeton, New Jersey. Mr. Gautam is with Dr. Reddy’s Laboratories SA in Basel, Switzerland. FUNDING: This study was funded and sponsored by Dr. Reddy’s Laboratories (DRL #841). DISCLOSURES: Dr. Sidgiddi, MD
by Sharleen St. Surin-Lord, MD; Todd E. Schlesinger, MD, FAAD; and Eric Guenin, PharmD, PhD, MPH Dr. St. Surin-Lord is with Visage Dermatology and Aesthetics Center in Largo, Maryland. Dr. Schlesinger is with the Clinical Research Center of the Carolinas in Charleston, South Carolina. Dr. Guenin is with Ortho Dermatologics in Bridgewater, New Jersey. FUNDING: Ortho
by Hazel H. Oon, MD, MRCP, FAMS; Su-Ni Wong, MBBS, MMed, FRCP, FAMS; Derrick Chen Wee Aw, MBBS, MRCP, FAMS; Wai Kwong Cheong, MBBS, MRCP, FRCP; Chee Leok Goh, MD, MMed, FRCP, FAMS; and Hiok Hee Tan, MBBS, MRCP, FRCP, FAMS Drs. Oon and Goh are with the National Skin Centre in Singapore. Dr. Wong is